Member Info for Johnski

Peak, absolutely brilliant, 'I Used To Be With It, But Then They Changed What It Was'.

https://pubmed.ncbi.nlm.nih.gov/2861567/

We must be cautious of those that appear at times like this, we all know who they are. They are playing a game with us, and it’s very easy to fall into their net.
They’ll keep you guessing about which version of them you’re getting. We have to stop trying to please them.
Toxic people figured out a long time ago that decent people will go to extraordinary lengths to keep the thing (Syme) they care about happy.
They will manipulate… toxic people have a way of sending out the vibe that you owe them something ie a definitive answer to a question LTH’s cannot answer.
They also have a way of taking from you or doing something that hurts you, then maintaining they were doing it all for you ie sell your shares! Sounds familiar?
They’ll make you prove yourself to them! How often does that happen on here!
They’ll twist the story, change the way it happened and retell it so convincingly that they’ll believe their own nonsense.
They’ll be there in a crisis but they’ll never ever share your joy. Come the day this SP goes north you’ll never hear from them again.
They’ll leave a conversation unfinished, and go offline.
They’ll use non-toxic words with a toxic tone.
When you’re trying to resolve something important to you, toxic people will bring in irrelevant detail from five arguments ago. The problem with this is that before you know it, you’re arguing about something you did six days ago, still defending yourself, rather than dealing with the issue at hand.
They’ll make it about the way you’re talking, rather than what you’re talking about.
They exaggerate.
We all get it wrong sometimes but toxic people will make sure you know it. They’ll judge you and take a swipe at your self-esteem suggesting that you’re less than because you made a mistake.
Strangemartian said it very well “The network being built is breathtaking”. Ignore the toxic negative and irrelevant, they will try and tell you that they are just looking for debate and blame you for not having the answers and use that against you. Ignore them and they will go away. Concentrate on the positive, to paraphrase Strangemartian, on the people AZ is investing in, drawing on all their experience, building a network which is thrilling, a journey through the Italian Riviera, magnifico!

I don’t see a problem.
SP is holding well.
The usual mob of derampers will recede as stability returns.
It is naïve to think the top priority of uninvested trolls on here are actually considering your financial welfare, wake up and smell the coffee, they are simply after your shares.
Negma will have been all over Syme, DD, assuring themselves that the strategic direction they are heading in shows promise.
They look closely at the needs of the company and the destination of the funds, corroborating accounts and ensuring there is no mismatch.
They visit offices, ensuring they understand the fundamentals of the Syme business, and are able to make informed, reasoned decisions.
They focus on providing companies with competitive, flexible terms that will allow Syme to concentrate on growing the business.
TF will have been fully involved too, have they pulled out, er, no. Look at the guys involved for goodness sake, they are all vastly experienced, anyone jumping ship, er, no.
I look on this a bit like my first mortgage, I wanted a particular house, I didn’t have enough money so I arranged with a lender so much then topped up the rest with my credit cards, I worked away for years, getting promoted, working at the business of becoming profitable and paid it off. It takes time.
Too many experienced professionals have joined this set up, and been happy, obviously, to stay and share what will be a success long term. Its an investment not a get rich quick scheme, go and be a day trader if you want that.
And Rodolfo Galbiati, Fund Director at Negma Group, Did a degree in aerospace engineering at Politecnico di Milano, maybe he knows AZ?
Pull yourselves together, put the kettle on and ignore the negative.

June 15 (Reuters) - AstraZeneca (AZN.L) said on Tuesday a late-stage trial failed to provide evidence that its COVID-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.

The study assessed whether the therapy, a ****tail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing COVID-19 symptoms.

The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.

But of course this is not our phase 2 trials of AZD1656

We must be mindful that only approximately 33% of phase 2 trials actually go on to phase 3, or to be developed further, (on average that is, with the caveat that I think only about 4% of cancer drugs get through but much higher % for say vaccines), however, there are known knowns (if I may be permitted to paraphrase Donald Rumsfeld);
AZD1656 has been shown to activate the migration of T regulatory cells to sites of inflammation in preclinical experiments, which is the main objective of this trial
And,
AZD 1656 has a blood glucose lowering effect for four months, which meets a major part of the second objective
And,
AZD 1656 has been found to be safe in almost 1,000 patients with diabetes and healthy patients in a set period of months.
These are known knowns!
Drugs do however sometimes complete a successful phase 2 then their efficacy fails at phase 3 testing, so grounds for optimism perhaps, despite the 66% failure rate.
Correct me if I am wrong please and DYOR of course. 3m and LTH

Main objective of the trial

To determine the effect of AZD1656 on the cardiorespiratory complications of COVID-19 in hospitalised diabetic patients with known or suspected COVID-19 disease, (ie inflammation of the heart muscle, pericarditis is inflammation of the lining outside the heart. In both cases, the body's immune system is causing inflammation in response to an infection)
AZD1656 (AZD1656 (GCK activator, 1 µM) has been shown to activate the migration of T regulatory cells to sites of inflammation in preclinical experiments. This migration of Treg cells to inflamed tissue is crucial for their immune-modulatory function (Kishore et al (2017) GCK activation significantly enhanced Treg cell migration to the inflamed tissue. Tregs not only maintain the tone and tenor of an immune response by dominant tolerance but have also been identified as key players in resolving tissue inflammation and as mediators of tissue healing
Research docs link;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714502/

Secondary objectives of the study

To assess the extent to which AZD1656 supports maintenance of adequate glycaemic control in hospitalised diabetic patients with known or suspected COVID-19. ie Glycemic control is a medical term referring to the typical levels of blood sugar (glucose) in a person with diabetes.
AZD 1656 has been found to be safe in almost 1,000 patients with diabetes and has a blood glucose lowering effect for four months ie IMO sufficient to cover the critical period likely in hospital with covid 19. Blood glucose control has been proposed as a key factor in reducing complications from COVID-19 in diabetics. Research docs link;
https://europepmc.org/article/med/22943931

To assess the safety and tolerability of AZD1656 in the management of diabetes in hospitalised diabetic patients with known or suspected COVID-19. AZD1656 has been studied in single doses of up to 180 mg and multiple doses to 150 mg BID for 8 days in healthy volunteers as well as alone and in combination with other blood glucose control agents in diabetic patients at 200 mg daily for up to 6 months duration. In both healthy volunteers and diabetic patients no significant clinical effects other than glucose lowering were noted. Research docs link;
https://openinnovation.astrazeneca.com/azd1656.html

To determine whether AZD1656 affects duration of hospital stay, requirement for mechanical ventilation or mortality in diabetic patients with known or suspected COVID-19.
To be determined in trial.

SGS has acquired the right to develop and commercialise two assets from a major global pharmaceutical company. Link to multiple (24) trials by AstraZenaca on AZD1656;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/SearchResults
I will be increasing my share numbers in the morning but DYOR!

"I asked to start a healthy debate but found a bunch of disturbed individuals".
Mmmm, not sure about your agenda now. You say you don't have one, but, I don't think your responses are typical of someone who is just looking for reassurance when suffering a wobble. looking at the answers people here have tried to say that what they have done is looked at everything involved with this company, as you can clearly see if you look back through the Board, and that you must come to your own conclusion, as we have. But you keep rejecting that so that's up to you. I'm going to get on with the business of monday now.

Holddddd
Like all of us, you must look at this yourself and come to a decision. Your investment is your responsibility, you cannot criticize anyone here from the rockets to the derampers, all life is here. When you press the 'buy' button, it is solely your responsibility, as is the moment you choose to press the 'sell' button.

"So far, cluelessness and childishness is all that is being shown.

More and more evidence of the mess we are all in".

My advice, for what's it's worth from a "cluelessness and childishness" perspective, is for you to sell up if you are that disillusioned. However, if you do have another motive for being here, then it will not influence lth's here. If you are genuine, then join the long line of concerned unwashed but who keep a core of belief that this will come good and could actually be very big. If i was you i would look at the people involved again and the enormity of what they are trying to achieve. I am clueless and childish of course so you must DYOR like any responsible adult.

Fool they motel, episode 2. (2 of 2)
“I’ve asked myself whether I should buy UK penny stock Supple@MeCapital? I’ll say straight off that I’ve concluded I should avoid it”. (ah ok I’ll sell up. Hello is that my HL broker? Hi yes please sell all my syme shares)
“I’ll explain my reasons for steering clear and also look at the potential upside, if my caution is misconceived”. (Wowww, hold the door HL, sorry, stop on that sale, phew)
“The company targeted a first securitisation of inventories via its platform within six months. But, so far, it hasn’t managed to bring together a single deal”. (ok fair enough, HL yep sell em please, sorry about the mix up earlier)
“I’ve previously” (err, you mean no longer right?) “been sceptical about Supply@Me’s prospects. For one thing, I’m not convinced the company’s business model is actually viable”. (well thank goodness I’ve sold then)
“First, Supply@Me was sold to investors on a prospectus showing net assets of £227m — bang in line with its market capitalisation at an issue price of 0.7p a share. However, on its post-listing balance sheet, net assets were less than £1m. Goodwill had been entirely written off”. (well there you go, sale justified)
“Waiting for Godot” (Beckett wanted to explore waiting of course, describing a situation where they are waiting for something to happen, but it probably never will. Phew, lucky break for me then, thanks guys)
“the publication of this penny stock’s first audited financial statements has been put back and back.” (Fair enough)
“In view of the net assets carry-on, and the repeated delays to both the first securitisation of inventories and first audited results, Supply@Me doesn’t pass my smell test”. (ah yes, A hypothetical pass/fail "test" that gauges the moral acceptability or trustworthiness of someone or something, well I’m following your nose, if you see what I mean).
“I’d want to at least see those audited results before going anywhere near this penny stock”. (Yeah me too, although, not any more because I just sold up)
“But what if my scepticism is misconceived”? (WHAT?!)
“if the company really has found a way to revolutionise inventory monetisation through its fintech platform, the market opportunity could be vast. Supply@Me talks of an addressable market of inventory under management in the $trillions. Not a bad target for a little UK penny stock!” (HOLY CRAP! Hello, hello! is that my broker, I need to get him its mega urgent!)

David Cameron...????? I have no idea Brass. I'm just a simple bloke, unsophisticated, living on a croft in Scotland's beautiful country. I haven't read anything related to David Cameron since he abrogated his responsibilities as Prime minister and called a referendum allowing the conservative right to take us out of Europe. (By the way B&Q have no cement in stock because of supply problems and a lack of HGV drivers who have all gone back to their EU countries). If you are referring to his views regarding Greensill? I haven't read his comments. I make my own mind up about business, shares, my money and my own gut feeling.

to try to rationalise why we would 'spend' our thousands of hard earned money on this is difficult. I think its because on the one hand you look at as many aspects of this company as you can, and try to understand the concepts, which are challenging, and you come to a decision to put money in on that business head assessment. But, critics say its partly a sentimental punt. I think sometimes, you just have a 'feeling' about something. You might be scanning Pinterest or a design post and something instinctively attracts you. I do think the concept of Syme attracts us in an emotional way like no other share. We should be cold, clear headed, focused only on the business aspects, and we are as far as that can take us, but we are human, and i think a gut feeling is just as valid.

Various comments re ramping re negativity etc
I believe in SYME because I have looked at what they are doing, people involved, like these two. I believe in their track record. This is not ramping, these are solid factual credentials.
Tony Brown, Strategic Adviser to Supply@ME
• Retained by an early stage international trade payables platform to support their equity raise and develop the U.S., Canadian and overseas markets for their service
• Providing international trade strategy and market/product development advice to two fintech specialist startups in blockchain and AI/data science
• Expert witness in an alleged $70MM receivables finance fraud
• Consulted to a Trade Finance Solutions and Hitachi Capital to create Hitachi Inventory Procurement, a groundbreaking procurement solution for large corporations that seek to improve liquidity and/or balance sheet metrics and lower their landed cost of goods.
• Retained by a leading global bank's asset finance group to identify opportunities to invest capital in successful U.S.-based factoring, asset based lending, supply chain finance and Purchase Order Finance firms
• Special adviser to the Commercial Finance Association to launch an annual factoring & supply chain finance conference (now in its 4th year), including thought leadership, panel topics and selection of speakers.
• Designed and conducted an international trade finance training program for global roll-out to internal sales and account management resources
• Retained by a global bank leader in U.S. middle market asset based lending (ABL) and factoring to develop new cross-border trade finance products and strategies.
• Engaging public speaker, panel moderator and author of thought leadership articles
• Council Member at Gerson Lehrman Group
etc
Tom James CEO CoFounder Tradeflow
Tom has been digitising the commodity industry since 1998 when he designed and launched the first ever online digital ID secured trading platform for the commodity swaps market. In 2016 he was the solution architect for and co-founder of TradeFlow Capital the Innovative AI powered FinTech Fund Management company. TradeFlow's Digital Transaction and Risk Transformation Architecture enables global physical commodity trade for SME’s via an innovative non-credit, non-lending model which also provides superior risk adjusted returns and capital protection for investors. The approach is also collaborative with traditional lending institutions such as Banks and other lenders, creating Hybrid finance opportunities unlocking liquidity.

Why on earth would I believe the derampers, the negativity on here, more than these people? I don’t have to justify MY beliefs, where I put MY money, I don’t care what glass half empty people think, I may lose all my kids inheritance, but I’m pretty sure I will not, and if I do, well I’ll just tick it down to experience and go out and get a job. Nothing to do with anyone else.

Quality and cumulative decades of experience of people involved in Syme and TR combined.
Sharia Scholar Board authorization
Quadrivio
Captive bank
New funders
Confirmed IFRS compliance of structure. (International Financial Reporting Standards (IFRS) set common rules so that financial statements can be consistent, transparent, and comparable around the world. IFRS are issued by the International Accounting Standards Board (IASB)
USA. Anthony Brown, founder and CEO of The Trade Advisory, has more than thirty years of international supply chain finance experience as a trader, lender, shipper, supply chain and business executive. He pioneered Purchase Order Financing in the US and headed International Factoring for GMAC Commercial Finance (now Ally Financial). A unique opportunity to develop Supply@ME's Inventory Monetisation service in the United States. The Trade Advisory estimates there are 114 asset-based lending operators in the US with an inventory finance market worth more than US$1trn.
Tom James, “The combination of the expertise in TradeFlow Capital and Supply@ME, will broaden our shared geographic footprint and create a global digitised offering which will create a number of benefits from both a funding, technology and customer origination perspective”.

These people aren’t messing about, they mean serious business. I believe this is a dead cert. Ladies and gentlemen…this is about to be our finest hour!

nei prossimi giorni...I hope so

10,000 children die every day from starvation...its a very unfair world

AZD1656 may have two possible effects on people with COVID-19 and diabetes.
1) Helping control blood glucose levels. (This has been demonstrated in previous clinical trials (960 people in 25 previous trials), with diabetic patients. Because the effects only last about 4 months it has not been considered as a long term treatment). The reason blood glucose control may be important in COVID-19 is that some studies have shown people with diabetes and with hyperglycaemia (high blood glucose levels) during COVID-19 infection may have worse outcomes than those who do not have hyperglycaemia.
2) The second potential effect of AZD1656 is that it may help reduce excessive inflammation in the lungs and other organs, which is sometimes seen in patients with COVID-19. It is thought it does this by activating the body’s own immune system, specifically T regulatory cells, and sending them to the areas of inflammation. Their effect on inflammation has not yet been proven and is being studied during this trial.
To date 174m cases, 3.75m deaths worldwide.
A Lancet Diabetes & Endocrinology study mining 61 million medical records in the U.K. says 30% of Covid-19 deaths occurred in people with diabetes. After accounting for potentially relevant risk factors such as social deprivation, ethnicity, and other chronic medical conditions, the risk of dying from Covid-19 was still almost three times higher for people with type 1 diabetes and almost twice as high for type 2, versus those without diabetes. That is just the UK. Clearly with covid still raging in parts of the world where diabetes is common, AZD1656 might be able to reduce tremendous suffering and loss of life.

it will hopefully help many people with mucormycosis from COVID-19 in diabetics, but I would have thought the great potential for this drug (correct me if i am wrong) is the control of sugar levels in diabetes. In clinical studies this drug, SGS002, has been found to be safe in almost 1,000 patients with diabetes and has a blood glucose lowering effect for four months.
415 million people are living with diabetes in the world, which is estimated to be 1 in 11 of the world's adult population. 46% of people with diabetes are undiagnosed.
Huge potential. Haven't worked out the SP should it become a treatment.

25th May Motley Fool
“The Supply@Me Capitol share price has had an interesting first year of trading” (ok I’ll buy)
“I think it’s fair to say this is a volatile stock” (oh should I sell then)
“And while it’s too soon to tell”, (ah I should sell) “I think Supply@Me could be a viable business capable of substantial growth” (oh great I’ll get on to HL right away)
“it’s an interesting idea” (superb, hello is that my Broker…)
“that could carry the SYME share price higher if successful” (tell him I need to buy stock as soon as!)
“And based on the latest results from March this year, it has attracted some attention” (well where is he, having a tea break?! I’m losing money here mate)
“As promising as this business idea may be” (er…yeah..I sense a, but…)
“it’s far from risk-free” (hold on dragging my broker out of the loo)
“there appears to be quite a high level of uncertainty among investors”. (I should sell then?)
“The business is not a profitable venture at this stage” (oh, but you just said it’s a promising business?)
“Should it fail to retain or attract businesses to its platform, creditors will find it more difficult to regain their original capital. Consequently, they will likely reduce their purchasing of other inventory assets, leading to the platform effectively becoming unusable” (oh bum, so why am I here at all, tell my Broker I don’t need him now)
“Based on existing performance, I think this is an unlikely scenario”.(oh make yer mind up mate, I just told my Broker he’s off the case)
“But at this early stage, it is a possibility” (so I shouldn’t buy then? I’m getting a bit dizzy)
“the valuation does seem a bit rich for my tastes” (defo not then)
“I’ll be keeping my eye on this business” (what for? you just told me its not for me, you see I need to get in early chum, basically you don’t know do you?)
“But for now, I won’t be adding any shares to my portfolio” (who are you again?)
“I think there are far better growth opportunities available today” (ok so what are they then? and if they are better opportunities, why are you not sunning yourself in some caribbean tropical paradise on a rattan sunlounger with a tequila in yer hand? Answer me that then)